04 Dec, 2013
Affinity Life Sciences to commercialize HyTest’s proprietary SES-BNP™ technology
HyTest and Affinity Life Sciences (AFF) have signed a licensing agreement that allows AFF to develop and commercialize a research use only ELISA-kit based on HyTest’s proprietary SES-BNP™ technology.
Read more
24 Oct, 2013
HyTest participates in NextDx EU-funded consortium to develop new highly sensitive blood testing technology
eading companies and institutes in protein diagnostics and micro-nano-bio research, including Philips, imec, Hytest, PolyAn, Bremen University and Eindhoven University of Technology, have joined forces
Read more
16 Oct, 2013
HyTest attending Medica trade fair in November 2013
HyTest participates in Medica exhibition in November 20th - 23rd. Welcome to visit our booth D64 in hall three at any time.
Read more
13 Jul, 2013
Meet Us at AACC Houston
It's again time for AACC. This time Houston will be the place where the world of laboratory medicine will come together.
Read more
18 Jun, 2013
Half-year Financial Report
Over the past half-year, HyTest consolidated sales amounted to EUR 6.3 million.
Read more
13 May, 2013
HyTest anti-cTnI antibodies utilized in a novel, highly sensitive cTnI assay
LamdaGen’s new diagnostic platform allows rapid and reproducible quantification of cTnI from whole serum.
Read more
05 May, 2013
HyTest awarded an Achiever Certificate
A company’s strong financial position shows that partnerships can be built on a solid foundation and can withstand economic fluctuations.”
Read more
28 Nov, 2012
Monoclonal antibody to glycated hemoglobin (HbA1c)
Diabetes causes substantial health costs because of complications associated with it and therefore repeated glucose measurements are an essential part of diabetes daily care.
Read more
04 Nov, 2012
HyTest attends to MEDICA 2012 in Düsseldorf in November
HyTest attends to MEDICA 2012 in Düsseldorf in November. You are warmly welcome to pass by at our booth # 3D64 .
Read more
21 May, 2012
HyTest excellent half year growth
Year to year revenue growth was 18%. Hytest profitability continues to be on high level even though HyTest has been investing to China operations and IP-portfolio amongst other things.
Read more
10 Jan, 2012
HyTest’s strong growth continues
HyTest’s revenue at the end of October for the fiscal year 2010-2011 year was EUR 10.2 million. HyTest was again capable of growing its market share as growth over the previous year was 12% which exceeds the industry average.
Read more
21 Jun, 2011
HyTest abstract has won National Academy of Clinical Biochemistry Distinguished Abstract Award
HyTest attends to AACC 2011 Clinical Expo in Atlanta, July 25-28. You are warmly welcome to visit our booth #27 at any time.
Read more
25 May, 2011
HyTest revenue increased 15 % - press release first half of fiscal year 2011
Sales of cardiac markers increased significantly during the period and there was especially remarkable growth in the sales of troponin-products.
Read more
14 Feb, 2011
Licensing opportunities – technology solution for BNP- and proBNP -detection
Interested in entering the fast growing cardiac diagnostics market with a new innovative diagnostics solution?
Read more
05 Feb, 2011
Strong growth of HyTest continues – revenue almost 10 million euros
HyTest revenue increased by 17% to 9.1 million euros and the operating profit was 3.1 million euros and in percentage 34%.
Read more
17 May, 2010
D-dimer and High Molecular Weight Fibrin Degradation
HyTest offers D-dimer produced from clotted fibrinogen by means of plasmin digestion and anti-D-dimer MAbs.
Read more
15 Apr, 2010
Antibodies for New Type of BNP immunoassay – “Single Epitope Sandwich” assay
HyTest specialists have recently developed antibodies for a brand new type of BNP immunoassay
Read more

Do you need samples?

We are happy to make you an offer